NasdaqGS:DXCMMedical Equipment
The Bull Case For DexCom (DXCM) Could Change Following Expanded Type 2 CGM Reimbursement Access - Learn Why
Earlier this year, DexCom highlighted that expanded insurance reimbursement now gives its continuous glucose monitoring systems access to a large group of type 2 non-insulin diabetes patients, while recent Q2 clinical data and product updates underscored the medical benefits of broader CGM use.
This combination of wider coverage and strong evidence base is reshaping expectations for DexCom’s long-term demand profile and business mix, even as competition and pricing uncertainties remain...